Diedaravone phosphate ester compounds, preparation methods and uses thereof
Through the chemical structure modification of bisedaravone phosphate compounds and new preparation methods, the problem of insufficient solubility and stability of edaravone drugs has been solved, and higher bioavailability and efficacy have been achieved, which is suitable for the brain. Clinical application of protective agents.
Patent Information
- Application Number
- CN202210797257.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-06
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2042-07-06
AI Technical Summary
The insufficient solubility and stability of existing edaravone drugs lead to problems such as difficulty in use and poor pharmacokinetic properties in clinical applications.
A di-edaravone phosphate compound and its pharmaceutically acceptable salts and organic amine salts have been developed to increase bioavailability through chemical structural modifications and release active drugs through enzymatic or non-enzymatic conversion, using new Preparation method improves the solubility and stability of the drug.
It improves the bioavailability and efficacy of edaravone, enhances the solubility and stability of the drug, reduces toxic side effects, and is suitable for drug applications of brain protective agents.
Smart Images

Figure CN115073518B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic compound synthesis and pharmaceutical application, and specifically relates to a bisedaravone phosphate compound, and a preparation method and use thereof. Background Art
[0002] Edaravone, trade name Bicun, is a brain protective agent that has been listed in recent years. It has a strong free radical scavenging effect. Edaravone can scavenge free radicals and inhibit lipid peroxidation, thereby inhibiting oxidative damage to brain cells, vascular endothelial cells, and nerve cells. Edaravone exists in the form of edaravone anions in the body, and reacts with free radicals such as light free radicals produced in the ischemic focus during cerebral ischemia and reperfusion. During this period, edaravone provides the electrons it carries to one side of the free radical to achieve the purpose of scavenging free radicals and making them harmless. In clinical practice, it can be used to treat not only cerebrovascular disorders, but also acute brain injuries caused by various reasons.
[0003] However, at present, edaravone is only available as a water injection for intravenous drip, and edaravone is dissolved in propylene glycol in the preparation, and various stabilizers and antioxidants are added. A large amount of organic solvents with hemolytic effect are used in the preparation, and the stability of the drug is poor. When used, it needs to be temporarily prepared and dripped completely within half an hour. The art still needs to develop edaravone derivatives with better solubility, better stability and better pharmacokinetic properties. Summary of the invention
[0004] The object of the present invention is to provide a bisedaravone phosphate ester compound, isomers or pharmaceutically acceptable salts thereof on the basis of the prior art.
[0005] Another object of the present invention is to provide a method for preparing the above-mentioned edaravone phosphate ester compounds and isomers.
[0006] The third object of the present invention is to provide a method for preparing the pharmaceutically acceptable metal salts of the above compounds.
[0007] The fourth object of the present invention is to provide a method for preparing the pharmaceutically acceptable organic amine salt of the above compound.
[0008] The fifth object of the present invention is to provide a pharmaceutical composition, which uses edaravone phosphate ester compounds, isomers or pharmaceutically acceptable salts thereof as active ingredients or main active ingredients, supplemented with pharmaceutically acceptable carriers.
[0009] The sixth object of the present invention is to provide the use of the above-mentioned edaravone phosphate ester compounds, isomers or pharmaceutically acceptable salts thereof in the preparation of drugs related to brain protective agents.
[0010] The technical solution of the present invention is as follows:
[0011] The compound, isomer, and pharmaceutically acceptable salt of formula I,
[0012]
[0013] in,
[0014] X 1 Represents O or S;
[0015] R 1 Represents hydrogen, C 1 -C 6 Alkyl, substituted C 1 -C 6 Alkyl, cyclopropyl, cyclohexyl, substituted cyclohexyl, phenyl, substituted phenyl, benzyl, substituted benzyl, the substituted C 1 -C 6 The alkyl, substituted cyclohexyl, substituted phenyl or substituted benzyl may be optionally substituted by the following substituents: 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, cyano or nitro;
[0016] The pharmaceutically acceptable salt is a metal salt or an organic amine salt, wherein the metal salt is a lithium salt, a sodium salt, a potassium salt, a magnesium salt, a calcium salt or an aluminum salt; and the organic amine salt is a methylamine salt, a dimethylamine salt, a trimethylamine salt, an ethylamine salt, a diethylamine salt, a triethylamine salt, an ethanolamine salt, a piperazine salt, a dibenzylethylenediamine salt, a meglumine salt, a tromethamine salt, a tetramethyl quaternary ammonium salt, a tetraethyl quaternary ammonium salt, a choline salt, a lysine salt or an arginine salt.
[0017] The edaravone phosphate ester compound, isomer or pharmaceutically acceptable salt thereof provided by the present invention is a prodrug of edaravone, and its main purpose is to improve the bioavailability of the drug, increase the stability of the drug, reduce the toxic side effects, and promote the long-term effect of the drug. The edaravone phosphate ester compound obtained after chemical structure modification is inactive or less active in vitro, and releases active drugs through enzymatic or non-enzymatic conversion in vivo to exert its efficacy.
[0018] In a preferred embodiment, R 1 Represents hydrogen, C 1 -C 4 Alkyl, substituted C 1 -C 4 Alkyl, cyclohexyl, substituted cyclohexyl, phenyl, substituted phenyl, benzyl, substituted benzyl, the substituted C 1 -C 4 The alkyl, substituted cyclohexyl, substituted phenyl or substituted benzyl radicals may optionally be mono- or polysubstituted by methyl, ethyl, methoxy or ethoxy radicals.
[0019] In a more preferred embodiment, R 1 represents hydrogen, ethyl, butyl, cyclohexyl, phenyl or benzyl.
[0020] The pharmaceutically acceptable salts mentioned in the present invention are metal salts, which may be lithium salts, sodium salts, potassium salts, magnesium salts or calcium salts.
[0021] Furthermore, the pharmaceutically acceptable salt is an organic amine salt, which may be an ethylamine salt, a triethylamine salt, an ethanolamine salt, a piperazine salt, a dibenzylethylenediamine salt, a meglumine salt, a choline salt, a lysine salt or an arginine salt.
[0022] For the present invention, X 1 Represents O or S, R 1 When represents hydrogen, the structural formula of the pharmaceutically acceptable metal salt of the compound represented by Formula I is as follows:
[0023]
[0024] Wherein, M represents lithium ion, sodium ion, potassium ion, magnesium ion, calcium ion or aluminum ion. Since the metal represented by M has valences of positive 1, positive 2 and positive 3, the compound shown in Formula II cannot accurately express the specific structure of the metal salt. According to the different valences, its specific general formula can be divided into the following types:
[0025]
[0026] For the present invention, X 1 Represents O or S, R 1 When represents hydrogen, the structural formula of the pharmaceutically acceptable organic amine salt of the compound represented by Formula I is as follows:
[0027]
[0028] Wherein, B represents methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, ethanolamine, piperazine, dibenzylethylenediamine, meglumine, tromethamine, tetramethyl quaternary amine, tetraethyl quaternary amine, choline, lysine or arginine. Due to the different number of N atoms in the organic amine represented by B, the compound shown in formula III cannot accurately express the specific structure of the organic amine salt, and its specific general formula can be divided into the following types:
[0029]
[0030] In a preferred embodiment, the compound represented by formula I, isomer or pharmaceutically acceptable salt thereof mentioned in the present invention is selected from:
[0031]
[0032]
[0033] The present invention discloses a method for preparing a compound and an isomer of the general formula I. 1 Represents O or S, R 1 When represents hydrogen, the preparation method of the compound represented by general formula I comprises the following steps:
[0034]
[0035] When X 1 Represents O, R 1 When represents hydrogen, the preparation method of the compound represented by general formula I comprises the following detailed steps:
[0036]
[0037] (1) adding an organic base acid-binding agent to a solvent, and after mixing evenly, adding phosphorus oxychloride dropwise;
[0038] (2) Adding edaravone to the mixed solution prepared in step (1) to carry out a chemical reaction to prepare edaravone phosphate, i.e., the compound represented by the above formula I, compound 1.
[0039] The solvent is one or more of dichloromethane, dichloroethane, chloroform, carbon tetrachloride, tetrahydrofuran, ethyl acetate, toluene, benzene, diethyl ether, methyl tert-butyl ether, and ethylene glycol dimethyl ether, preferably dichloromethane.
[0040] The organic base acid-binding agent may be, but is not limited to, triethylamine, pyridine, and N-methylmorpholine, preferably triethylamine.
[0041] When X 1 Represents S, R 1 When represents hydrogen, the preparation method of the compound represented by general formula I comprises the following detailed steps:
[0042]
[0043] (1) dissolving edaravone phosphate in a solvent;
[0044] (2) sulfur and an organic base acid-binding agent are added to the mixed solution prepared in step (1), and the mixture is stirred for reaction to prepare diedaravone thiophosphate, i.e., the compound shown in formula I, compound 2.
[0045] The solvent is one or more of dichloromethane, dichloroethane, chloroform, carbon tetrachloride, tetrahydrofuran, ethyl acetate, toluene, benzene, diethyl ether, methyl tert-butyl ether, and ethylene glycol dimethyl ether, preferably dichloromethane.
[0046] The organic base acid-binding agent may be, but is not limited to, triethylamine, pyridine, and N-methylmorpholine, preferably triethylamine.
[0047] When X 1 Represents O, R 1 When does not represent hydrogen, the preparation method of the compound or isomer represented by the general formula I comprises the following steps:
[0048]
[0049] Among them, X 2 Represents chlorine, bromine or hydroxyl.
[0050] In a preferred embodiment, when X 1 Represents O, R 1 When does not represent hydrogen, the preparation method of the compound and isomers represented by the general formula I comprises the following detailed steps:
[0051] (1) adding an organic base acid-binding agent to a solvent, and after mixing evenly, adding phosphorus oxychloride dropwise;
[0052] (2) Adding edaravone to the mixed solution prepared in step (1) to carry out a chemical reaction to prepare edaravone phosphate, i.e., compound 1.
[0053] (3) Under the action of an acid-binding agent, the obtained edaravone phosphate is reacted with compound IV in a solvent to undergo a substitution reaction to prepare a compound represented by formula I.
[0054] Among them, the acid binding agent is sodium carbonate, potassium carbonate, cesium carbonate, triethylamine, pyridine, N-methylmorpholine, preferably cesium carbonate.
[0055] The solvent is one or more of dichloromethane, dichloroethane, chloroform, carbon tetrachloride, tetrahydrofuran, ethyl acetate, toluene, benzene, diethyl ether, methyl tert-butyl ether or ethylene glycol dimethyl ether, preferably dichloromethane.
[0056] When X 1 Represents O or S, R 1 When represents hydrogen, the pharmaceutically acceptable metal salt of the compound of formula I is prepared by chemically reacting the compound of formula I with a metal hydroxide or a metal alcoholate in an alcohol solvent.
[0057] In a preferred embodiment, the method for preparing a pharmaceutically acceptable metal salt of the compound represented by formula I comprises the following steps:
[0058] (1) dissolving the compound represented by formula I (compound 1 or 2) in an alcohol solvent;
[0059] (2) Adding a metal hydroxide or a metal alcoholate to the mixed solution of step (1), and after the reaction is completed, concentrating to remove the solvent, and crystallizing from ethyl acetate to obtain a pharmaceutically acceptable metal salt of the compound represented by formula I.
[0060] Wherein, the metal hydroxide is lithium hydroxide, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide or aluminum hydroxide.
[0061] The metal alcoholate is sodium methoxide, sodium ethoxide, potassium tert-butoxide or sodium tert-butoxide.
[0062] The alcohol solvent is methanol, ethanol or isopropanol, preferably methanol.
[0063] When X 1 Represents O or S, R 1 When represents hydrogen, the pharmaceutically acceptable organic amine salt of the compound of formula I is prepared by chemically reacting the compound of formula I with an organic amine in an alcohol solvent.
[0064] (1) dissolving the compound represented by formula I (compound 1 or 2) in an alcohol solvent;
[0065] (2) adding an organic amine to the mixed solution of step (1) and stirring for reaction; after the reaction is completed, concentrating to remove the solvent, and crystallizing from ethyl acetate to obtain a compound of formula I and a pharmaceutically acceptable organic amine salt thereof.
[0066] Wherein, the organic amine is methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, ethanolamine, piperazine, dibenzylethylenediamine, meglumine, tromethamine, tetramethyl quaternary ammonium, tetraethyl quaternary ammonium, choline, lysine or arginine.
[0067] The alcohol solvent is methanol, ethanol or isopropanol, preferably methanol.
[0068] Unless otherwise specified, all technical terms used in the present invention have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. All patents and publications related to the present invention are incorporated herein by reference in their entirety.
[0069] Unless otherwise stated, the following terms used in the specification and claims have the meanings discussed below:
[0070] "Pharmaceutically acceptable salts" refers to those salts that retain the biological effectiveness and properties of the parent compound.
[0071] (1) Acid salts are obtained by reacting the free base of the parent compound with an inorganic acid or an organic acid. The inorganic acid includes hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, metaphosphoric acid, sulfuric acid, sulfurous acid and perchloric acid. The organic acid includes acetic acid, trifluoroacetic acid, propionic acid, acrylic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, oxalic acid, (D) or (L) malic acid, fumaric acid, maleic acid, ascorbic acid, camphoric acid, benzoic acid, hydroxybenzoic acid, γ-hydroxybutyric acid, methoxybenzoic acid, phthalic acid, methanesulfonic acid, ethanesulfonic acid, naphthalene-1-sulfonic acid, naphthalene-2-sulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid, lactic acid, cinnamic acid, dodecyl sulfuric acid, gluconic acid, glutamic acid, aspartic acid, stearic acid, mandelic acid, succinic acid, glutaric acid or malonic acid.
[0072] (2) Salts formed by the replacement of acidic protons in the parent compound by metal ions or by coordination with organic bases. Examples of metals include alkali metal ions, alkaline earth metal ions or aluminum ions; and organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, quinine, etc.
[0073] "Pharmaceutical composition" refers to a mixture of one or more of the compounds of the present invention or their pharmaceutically acceptable salts, solvates, hydrates or prodrugs with other chemical components, such as pharmaceutically acceptable carriers. The purpose of a pharmaceutical composition is to facilitate the process of administration to an animal.
[0074] "Pharmaceutical carrier" or "pharmaceutically acceptable carrier" refers to an inactive ingredient in a pharmaceutical composition that does not cause significant irritation to the organism and does not interfere with the biological activity and properties of the administered compound, such as but not limited to: calcium carbonate, calcium phosphate, various sugars (such as lactose, mannitol, etc.), starch, cyclodextrin, magnesium stearate, cellulose, magnesium carbonate, acrylic acid polymers or methacrylic acid polymers, gelatin, water, polyethylene glycol, propylene glycol, ethylene glycol, castor oil or hydrogenated castor oil or polyethoxylated hydrogenated castor oil, sesame oil, corn oil, peanut oil, etc.
[0075] "Alkyl" means a saturated aliphatic hydrocarbon group of 1-20 carbon atoms, including straight and branched groups (the numerical ranges mentioned in this application, such as "1-20", mean that the group, in this case an alkyl group, may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms). More preferably, the alkyl group is a medium-sized alkyl group having 1-10 carbon atoms, such as methyl, ethyl, propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, etc. Preferably, the alkyl group is a lower alkyl group having 1-4 or 1-6 carbon atoms, such as methyl, ethyl, propyl, 2-propyl, n-butyl, isobutyl or tert-butyl, etc. The alkyl group may be substituted or unsubstituted. When it is a substituted alkyl group, the substituent is preferably one or more, more preferably 1-3, and most preferably 1 or 2 substituents.
[0076] "Hydroxy" means an -OH group.
[0077] "Nitro" means -NO 2 Group.
[0078] "Cyano" means a -CN group.
[0079] "Phenyl" means Group.
[0080] "Benzyl" means Group.
[0081] Cyclohexyl means Group.
[0082] "Alkoxy" refers to -O-(unsubstituted alkyl) and -O-(unsubstituted cycloalkyl). Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0083] Isomers include "stereoisomers" and "tautomers". "Stereoisomers" refer to compounds with the same chemical structure but different arrangements of atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers, (cis / trans) isomers, atropisomers, and the like. "Enantiomers" refer to two isomers of a compound that are not superimposable but are mirror images of each other. "Diastereomers" refer to stereoisomers with two or more chiral centers and whose molecules are not mirror images of each other. Diastereoisomers have different physical properties, such as melting points, boiling points, spectral properties and reactivity. Diastereomeric mixtures can be separated by high-resolution analytical operations such as electrophoresis and chromatography, for example HPLC. "Tautomers" or "tautomeric forms" refer to structural isomers with different energies that can be converted into each other through low energy barriers. If tautomerism is possible (such as in solution), a chemical equilibrium of tautomers can be achieved. For example, proton tautomers (protontautomers) (also known as prototropic tautomers) include interconversions by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions by the reorganization of some bonding electrons. A specific example of keto-enol tautomerism is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-ene-2-one tautomers. Another example of tautomerism is phenol-keto tautomerism. A specific example of phenol-keto tautomerism is the interconversion of pyridine-4-ol and pyridine-4 (1H) -one tautomers. Unless otherwise indicated, all tautomeric forms of the compounds of the present invention are within the scope of the present invention.
[0084] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and where it does not.
[0085] In addition, the compounds disclosed in the present invention can be administered in the form of prodrugs. In the present invention, the "prodrug" of the compounds disclosed in the present invention is a functional derivative that can eventually release the compounds disclosed in the present invention in vivo when administered to a patient.
[0086] The term "prodrug" used in the present invention refers to a compound that is converted into a compound of formula (I) or (II) in vivo. Such conversion is affected by the hydrolysis of the prodrug in the blood or the conversion of the prodrug into the parent structure by enzymes in the blood or tissues. The prodrug compounds of the present invention can be esters. In the existing invention, the esters can be aromatic esters, aliphatic (C1-C24) esters, acyloxymethyl esters, carbonates, carbamates and amino acid esters of prodrugs. For example, a compound in the present invention contains a hydroxyl group, which can be acylated to obtain a compound in the form of a prodrug. Other prodrug forms include phosphate esters, such as these phosphate ester compounds obtained by phosphorylation of the hydroxyl group on the parent.
[0087] The present invention also provides a pharmaceutical composition, which uses edaravone phosphate ester compounds, isomers or pharmaceutically acceptable salts thereof as active ingredients or main active ingredients, and is supplemented with pharmaceutically acceptable carriers.
[0088] The edaravone phosphate ester compound, isomer or pharmaceutically acceptable salt thereof provided by the present invention is a prodrug compound of edaravone, which can be rapidly converted into the original drug edaravone in plasma. Compared with the original drug edaravone, the edaravone phosphate ester compound, isomer or pharmaceutically acceptable salt thereof provided by the present invention has better solubility, drug stability and toxic side effects, improves bioavailability, enhances drug efficacy, and can be applied to drugs related to brain protective agents.
[0089] Adopt the technical scheme of the present invention, the advantages are as follows:
[0090] The edaravone phosphate ester compound, isomer or pharmaceutically acceptable salt thereof provided by the present invention is a prodrug compound of edaravone, which can be rapidly converted into the original drug edaravone in plasma. Compared with the original drug edaravone, the edaravone phosphate ester compound, isomer or pharmaceutically acceptable salt thereof provided by the present invention has better solubility, drug stability and toxic side effects, improves bioavailability, enhances drug efficacy, and can be applied to drugs related to brain protective agents. DETAILED DESCRIPTION
[0091] The present invention will be further described below in conjunction with specific embodiments. These embodiments are only for the purpose of explanation, rather than limiting the scope and essence of the present invention.
[0092] 1H-NMR was measured with a WNMR-I-400 / 500MHz instrument, and MS was measured with an Agilent 1100LC / MS instrument. The reagents used, such as dichloromethane and acetonitrile, were purchased from Anage Chemical Reagent Co., Ltd. Deuterated DMSO was purchased from J&K Chemical Reagent Co., Ltd. All solvents were redistilled before use, and the anhydrous solvents used were obtained by drying according to standard methods; the purification of the products was performed using silica gel (200-300 mesh) column chromatography unless otherwise specified; the silica gel (200-300 mesh) was produced by Qingdao Ocean Chemical, and the thin layer silica gel plate was produced by Yantai Jiangyou Silica Gel Development Co., Ltd.
[0093] Embodiment 1:
[0094] Nitrogen was introduced into a dry three-necked flask, and then 50 mL of dry dichloromethane was added. 6.10 g of triethylamine was added to dichloromethane, stirred, cooled to 5-10 ° C, and 4.40 g of phosphorus oxychloride was added dropwise, and the temperature was controlled to be below 10 ° C. After the addition, the temperature was cooled to 0 ° C, and 10.00 g of edaravone was added in batches, and the temperature was controlled to 0-5 ° C. After the addition, the temperature was naturally raised and reacted at room temperature for 2 hours. 30 mL of water was added for washing. The organic phase was separated by layers and washed once with 30 mL of water. The organic phase was separated and dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was passed through a column (DCM / MeOH=10 / 1) to obtain 12.0 g, which was diedaravone phosphate (Compound 1). Liquid area normalization purity: 98.9%, LCMS (E-) m / z: 411.4 (M+H). 1HNMR (400MHz, DMSO-d6) δ7.62-7.60(d,J=8,4H), 7.44-7.40(t,4H), 7.31-7.27(t,2H), 5.85(s,2H), 4.14(s,1H), 2.13(s,6H).
[0095]
[0096] Embodiment 2:
[0097] Nitrogen was introduced into a dry three-necked flask, and then 50 mL of dry dichloroethane was added. 6.10 g of triethylamine was added to dichloroethane, stirred, cooled to 5-10 ° C, and 4.40 g of phosphorus oxychloride was added dropwise, and the temperature was controlled to be below 10 ° C. After the addition, the temperature was cooled to 0 ° C, and 10.00 g of edaravone was added in batches, and the temperature was controlled to 0-5 ° C. After the addition, the temperature was naturally raised and the reaction was carried out at room temperature for 2 hours. 30 mL of water was added for washing. The organic phase was separated by layers and washed once with 30 mL of water. The organic phase was separated and dried over anhydrous magnesium sulfate, and the residue obtained by concentrating under reduced pressure was passed through a column (DCM / MeOH=10 / 1) to obtain 11.5 g, which was diedaravone phosphate (Compound 1). Liquid area normalization purity: 99.1%, LCMS (E-) m / z: 411.4 (M+H). 1HNMR (400MHz, DMSO-d6) δ7.62-7.60(d,J=8,4H), 7.44-7.40(t,4H), 7.31-7.27(t,2H), 5.85(s,2H), 4.14(s,1H), 2.13(s,6H).
[0098] Embodiment 3:
[0099] Nitrogen was introduced into a dry three-necked flask, and then 50 mL of dry chloroform was added. 6.10 g of triethylamine was added to chloroform, stirred, cooled to 5-10 ° C, and 4.40 g of phosphorus oxychloride was added dropwise, and the temperature was controlled to be below 10 ° C. After the addition, the temperature was cooled to 0 ° C, and 10.00 g of edaravone was added in batches, and the temperature was controlled to 0-5 ° C. After the addition, the temperature was naturally raised and reacted at room temperature for 2 hours. 30 mL of water was added for washing. The organic phase was separated by layers and washed once with 30 mL of water. The organic phase was separated and dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and the residue was passed through a column (DCM / MeOH=10 / 1) to obtain 10.6 g, which was diedaravone phosphate (Compound 1). Liquid area normalization purity: 99.1%, LCMS (E-) m / z: 411.4 (M+H). 1H NMR (400MHz, DMSO-d6) δ 7.62-7.60 (d, J = 8, 4H), 7.44-7.40 (t, 4H), 7.31-7.27 (t, 2H), 5.85 (s, 2H), 4.14 (s, 1H), 2.13 (s, 6H).
[0100] Embodiment 4:
[0101] Nitrogen was introduced into a dry three-necked flask, and then 50 mL of dry tetrahydrofuran was added. 6.10 g of triethylamine was added to tetrahydrofuran, stirred, cooled to 5-10 ° C, and 4.40 g of phosphorus oxychloride was added dropwise, and the temperature was controlled to be below 10 ° C. After the addition, the temperature was cooled to 0 ° C, and 10.00 g of edaravone was added in batches, and the temperature was controlled to 0-5 ° C. After the addition, the temperature was naturally raised and reacted at room temperature for 2 hours. 30 mL of saturated brine was added for washing. The organic phase was separated by stratification and washed once with 30 mL of saturated brine. The organic phase was separated and dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was passed through a column (DCM / MeOH=10 / 1) to obtain 10.6 g, which was diedaravone phosphate (Compound 1). Liquid area normalization purity: 98.7%, LCMS (E-) m / z: 411.4 (M+H). 1H NMR (400MHz, DMSO-d6) δ 7.62-7.60 (d, J = 8, 4H), 7.44-7.40 (t, 4H), 7.31-7.27 (t, 2H), 5.85 (s, 2H), 4.14 (s, 1H), 2.13 (s, 6H).
[0102] Embodiment 5:
[0103] Nitrogen was introduced into a dry three-necked flask, and then 50 mL of dry toluene was added. 6.10 g of triethylamine was added to toluene, stirred, cooled to 5-10 ° C, and 4.40 g of phosphorus oxychloride was added dropwise, and the temperature was controlled to be below 10 ° C. After addition, the temperature was cooled to 0 ° C, and 10.00 g of edaravone was added in batches, and the temperature was controlled to 0-5 ° C. After addition, the temperature was naturally raised and reacted at room temperature for 2 hours. 30 mL of water was added for washing. The organic phase was separated by layers and washed once with 30 mL of water. The organic phase was separated and dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and the residue was passed through a column (DCM / MeOH=10 / 1) to obtain 8.7 g, which was diedaravone phosphate (Compound 1). Liquid area normalization purity: 99.5%, LCMS (E-) m / z: 411.4 (M+H). 1H NMR (400MHz, DMSO-d6) δ 7.62-7.60 (d, J = 8, 4H), 7.44-7.40 (t, 4H), 7.31-7.27 (t, 2H), 5.85 (s, 2H), 4.14 (s, 1H), 2.13 (s, 6H).
[0104] Embodiment 6:
[0105] Nitrogen was introduced into a dry three-necked flask, and then 50 mL of dry methyl tert-butyl ether was added. 6.10 g of triethylamine was added to methyl tert-butyl ether, stirred, cooled to 5-10 ° C, and 4.40 g of phosphorus oxychloride was added dropwise, and the temperature was controlled to be below 10 ° C. After the addition, the temperature was cooled to 0 ° C, and 10.00 g of edaravone was added in batches, and the temperature was controlled to 0-5 ° C. After the addition, the temperature was naturally raised and reacted at room temperature for 2 hours. 30 mL of water was added for washing. The organic phase was separated by layers and washed once with 30 mL of water. The organic phase was separated and dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was passed through a column (DCM / MeOH=10 / 1) to obtain 9.5 g, which was diedaravone phosphate (Compound 1). Liquid area normalization purity: 99.0%, LCMS (E-) m / z: 411.4 (M+H). 1H NMR (400MHz, DMSO-d6) δ7.62-7.60 (d, J = 8, 4H), 7.44-7.40 (t, 4H), 7.31-7.27 (t, 2H), 5.85 (s, 2H), 4.14 (s, 1H), 2.13 (s, 6H).
[0106] Embodiment 7:
[0107] Nitrogen was introduced into a dry three-necked flask, and then 50 mL of dry dichloromethane was added. 4.77 g of pyridine was added to dichloromethane, stirred, cooled to 5-10 ° C, and 4.40 g of phosphorus oxychloride was added dropwise, and the temperature was controlled to be below 10 ° C. After addition, the temperature was cooled to 0 ° C, and 10.00 g of edaravone was added in batches, and the temperature was controlled to 0-5 ° C. After addition, the temperature was naturally raised and reacted at room temperature for 2 hours. 30 mL of water was added for washing. The organic phase was separated and washed once with 30 mL of water. The organic phase was separated and dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and the residue was passed through a column (DCM / MeOH=10 / 1) to obtain 11.5 g, which was diedaravone phosphate (Compound 1). Liquid area normalization purity: 99.1%, LCMS (E-) m / z: 411.4 (M+H). 1HNMR (400MHz, DMSO-d6) δ7.62-7.60(d,J=8,4H), 7.44-7.40(t,4H), 7.31-7.27(t,2H), 5.85(s,2H), 4.14(s,1H), 2.13(s,6H).
[0108] Embodiment 8:
[0109] Nitrogen was introduced into a dry three-necked flask, and then 50 mL of dry dichloromethane was added. 6.10 g of N-methylmorpholine was added to dichloromethane, stirred, cooled to 5-10 ° C, and 4.40 g of phosphorus oxychloride was added dropwise, and the temperature was controlled to be below 10 ° C. After the addition, the temperature was cooled to 0 ° C, and 10.00 g of edaravone was added in batches, and the temperature was controlled to 0-5 ° C. After the addition, the temperature was naturally raised and reacted at room temperature for 2 hours. 30 mL of water was added for washing. The organic phase was separated by layers and washed once with 30 mL of water. The organic phase was separated and dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and the residue was passed through a column (DCM / MeOH=10 / 1) to obtain 11.2 g, which was diedaravone phosphate (Compound 1). Liquid area normalization purity: 99.2%, LCMS (E-) m / z: 411.4 (M+H). 1H NMR (400MHz, DMSO-d6) δ 7.62-7.60 (d, J = 8, 4H), 7.44-7.40 (t, 4H), 7.31-7.27 (t, 2H), 5.85 (s, 2H), 4.14 (s, 1H), 2.13 (s, 6H).
[0110] Embodiment 9:
[0111] In a dry three-necked flask, nitrogen was introduced, 20 mL of anhydrous dichloromethane was added, 2 g of compound 1 was added to dichloromethane, and 0.16 g of sulfur was added, and stirred at room temperature for 15 hours. The solvent was removed by concentration, and 2.1 g of product was obtained by column, which was diedaravone thiophosphate (compound 2). Liquid area normalized purity: 99.3%, LCMS (E-) m / z: 427.4 (M+H). 1H NMR (400 MHz, DMSO-d6) δ7.62-7.60 (d, J=8, 4H), 7.44-7.40 (t, 4H), 7.31-7.27 (t, 2H), 5.85 (s, 2H), 4.14 (s, 1H), 2.13 (s, 6H).
[0112]
[0113] Embodiment 10:
[0114] In a dry three-necked flask, nitrogen was introduced, 20 mL of anhydrous methanol was added, 2 g of compound 1 was added to methanol, and 0.16 g of sulfur was added, and stirred at room temperature for 15 hours. The solvent was removed by concentration, and 2 g of product was obtained by column chromatography, which was diedaravone thiophosphate (compound 2). Liquid phase area normalized purity: 99.2%, LCMS (E-) m / z: 427.4 (M+H). 1HNMR (400 MHz, DMSO-d6) δ7.62-7.60 (d, J=8, 4H), 7.44-7.40 (t, 4H), 7.31-7.27 (t, 2H), 5.85 (s, 2H), 4.14 (s, 1H), 2.13 (s, 6H).
[0115] Embodiment 11:
[0116] In a dry three-necked flask, nitrogen was introduced, 20 mL of anhydrous tetrahydrofuran was added, 2 g of compound 1 was added to tetrahydrofuran, and 0.16 g of sulfur was added, and stirred at room temperature for 15 hours. The solvent was removed by concentration, and 1.95 g of product was obtained by column chromatography, which was diedaravone thiophosphate (compound 2). Liquid phase area normalized purity: 99.6%, LCMS (E-) m / z: 427.4 (M+H). 1H NMR (400 MHz, DMSO-d6) δ7.62-7.60 (d, J=8, 4H), 7.44-7.40 (t, 4H), 7.31-7.27 (t, 2H), 5.85 (s, 2H), 4.14 (s, 1H), 2.13 (s, 6H).
[0117] Embodiment 12:
[0118] In a dry three-necked flask, nitrogen was introduced, 20 mL of toluene was added, 2 g of compound 1 was added to toluene, and 0.16 g of sulfur was added, and stirred at room temperature for 15 hours. The solvent was removed by concentration, and 1.88 g of product was obtained by column chromatography, which was diedaravone thiophosphate (compound 2). Liquid area normalized purity: 99.3%, LCMS (E-) m / z: 427.4 (M+H). 1HNMR (400 MHz, DMSO-d6) δ7.62-7.60 (d, J=8, 4H), 7.44-7.40 (t, 4H), 7.31-7.27 (t, 2H), 5.85 (s, 2H), 4.14 (s, 1H), 2.13 (s, 6H).
[0119] Embodiment 13:
[0120] In a dry three-necked flask, nitrogen was introduced, 20 mL of methyl tert-butyl ether was added, 2 g of compound 1 was added to methyl tert-butyl ether, and 0.16 g of sulfur was added, and the mixture was stirred at room temperature for 15 hours. The solvent was removed by concentration, and 1.9 g of product was obtained by column chromatography, which was diedaravone thiophosphate (compound 2). Liquid phase area normalized purity: 99.3%, LCMS (E-) m / z: 427.4 (M+H). 1HNMR (400 MHz, DMSO-d6) δ7.62-7.60 (d, J=8, 4H), 7.44-7.40 (t, 4H), 7.31-7.27 (t, 2H), 5.85 (s, 2H), 4.14 (s, 1H), 2.13 (s, 6H).
[0121] Embodiment 14:
[0122] In a dry three-necked flask, nitrogen was introduced, 20 mL of anhydrous dichloromethane was added, 2 g of compound 1 was added to methanol, and 0.16 g of sulfur and 0.49 g of triethylamine were added, and stirred at room temperature for 15 hours. The solvent was removed by concentration, and 2 g of product was obtained by column chromatography, which was diedaravone thiophosphate (compound 2). Liquid area normalized purity: 99.3%, LCMS (E-) m / z: 427.4 (M+H). 1HNMR (400 MHz, DMSO-d6) δ7.62-7.60 (d, J=8, 4H), 7.44-7.40 (t, 4H), 7.31-7.27 (t, 2H), 5.85 (s, 2H), 4.14 (s, 1H), 2.13 (s, 6H).
[0123] Embodiment 15:
[0124] Add 20 mL of anhydrous dichloromethane to a dry three-necked flask, add 2 g of compound 1 to dichloromethane, then add 0.83 g of benzyl bromide and 2.38 g of cesium carbonate, and stir at room temperature for 15 hours. Filter and concentrate the filtrate. Add 20 mL of ethyl acetate to the resulting residue, heat to 60 ° C and stir for 2 hours. Cool to room temperature, filter, wash the filter cake with 10 mL of ethyl acetate, and dry the filter cake to obtain 1.9 g of compound 3. LCMS (E-) m / z: 501.2 (M+H).
[0125]
[0126] Embodiment 16:
[0127] Add 20 mL of anhydrous dichloromethane to a dry three-necked flask, add 2 g of compound 1 to dichloromethane, then add 0.83 g of benzyl bromide and 0.49 g of triethylamine, and stir at room temperature for 15 hours. Concentrate, add 20 mL of ethyl acetate to the residue, heat to 60 ° C and stir for 2 hours. Cool to room temperature, filter, wash the filter cake with 10 mL of ethyl acetate, and dry the filter cake to obtain 1.85 g of compound 3. LCMS (E-) m / z: 501.2 (M+H).
[0128] Embodiment 17:
[0129] Add 20 mL of anhydrous tetrahydrofuran to a dry three-necked flask, add 2 g of compound 1 to tetrahydrofuran, then add 0.83 g of benzyl bromide and 0.49 g of triethylamine, and stir at room temperature for 15 hours. Concentrate, add 20 mL of ethyl acetate to the residue, heat to 60 ° C and stir for 2 hours. Cool to room temperature, filter, wash the filter cake with 10 mL of ethyl acetate, and dry the filter cake to obtain 1.88 g of compound 3. LCMS (E-) m / z: 501.2 (M+H).
[0130] Embodiment 18:
[0131] Nitrogen was passed into a dry three-necked flask, and 25 mL of dry dichloromethane was added. 4.50 g of triethylamine was added to dichloromethane. Stir, cool to 5-10 ° C, and 2.20 g of phosphorus oxychloride was added dropwise, and the temperature was controlled below 10 ° C. After addition, the temperature was cooled to 0 ° C, and 5.00 g of edaravone was added in batches, and the temperature was controlled at 0-5 ° C. After addition, the reaction was kept warm for 1 hour, and 1.55 g of benzyl alcohol was added dropwise, and the temperature was controlled at 0-5 ° C. After addition, the temperature was naturally raised and reacted at room temperature for 2 hours. The solids in the reaction system were quickly filtered to remove the solids, and the filtrate was concentrated. The residue was passed through a column using neutral alumina to obtain 3.8 g of compound 3. LCMS (E-) m / z: 501.2 (M+H).
[0132] Embodiment 19:
[0133] Add 20 mL of anhydrous dichloromethane to a dry three-necked flask, add 2 g of compound 1 to dichloromethane, then add 0.67 g of bromobutane and 2.38 g of cesium carbonate, and stir at room temperature for 15 hours. Filter and concentrate the filtrate. Add 20 mL of ethyl acetate to the resulting residue, heat to 60 ° C and stir for 2 hours. Cool to room temperature, filter, wash the filter cake with 10 mL of ethyl acetate, and dry the filter cake to obtain 1.9 g of compound 4. LCMS (E-) m / z: 467.2 (M+H).
[0134]
[0135] Embodiment 20:
[0136] Nitrogen was passed into a dry three-necked flask, and 25 mL of dry dichloromethane was added. 4.50 g of triethylamine was added to dichloromethane. Stir, cool to 5-10 ° C, and 2.20 g of phosphorus oxychloride was added dropwise, and the temperature was controlled below 10 ° C. After addition, the temperature was cooled to 0 ° C, and 5.00 g of edaravone was added in batches, and the temperature was controlled at 0-5 ° C. After addition, the reaction was kept warm for 1 hour, and 1.06 g of n-butanol was added dropwise, and the temperature was controlled at 0-5 ° C. After addition, the temperature was naturally raised and reacted at room temperature for 2 hours. The solids in the reaction system were quickly filtered to remove the solids, and the filtrate was concentrated. The residue was passed through a neutral alumina column, and PE / EA=10 / 1 was used to obtain 3.4 g of compound 4. LCMS (E-) m / z: 467.2 (M+H).
[0137] Embodiment 21:
[0138] Add 20 mL of anhydrous dichloromethane to a dry three-necked flask, add 2 g of compound 1 to dichloromethane, add 0.79 g of bromocyclohexane and 2.38 g of cesium carbonate, and stir at room temperature for 15 hours. Filter and concentrate the filtrate. Add 20 mL of ethyl acetate to the residue, heat to 60 ° C and stir for 2 hours. Cool to room temperature, filter, wash the filter cake with 10 mL of ethyl acetate, and dry the filter cake to obtain 1.95 g of compound 5. LCMS (E-) m / z: 493.2 (M+H).
[0139]
[0140] Embodiment 22:
[0141] Nitrogen was passed into a dry three-necked flask, and 25 mL of dry dichloromethane was added. 4.50 g of triethylamine was added to dichloromethane. Stir, cool to 5-10 ° C, and 2.20 g of phosphorus oxychloride was added dropwise, and the temperature was controlled below 10 ° C. After addition, the temperature was lowered to 0 ° C, and 5.00 g of edaravone was added in batches, and the temperature was controlled at 0-5 ° C. After addition, the reaction was kept warm for 1 hour, and 1.44 g of cyclohexanol was added dropwise, and the temperature was controlled at 0-5 ° C. After addition, the temperature was naturally raised and reacted at room temperature for 2 hours. The solids in the reaction system were quickly filtered to remove the solids, and the filtrate was concentrated. The residue was passed through a neutral alumina column, and PE / EA=10 / 1 was used to obtain 3.7 g of compound 5. LCMS (E-) m / z: 493.2 (M+H).
[0142] Embodiment 23:
[0143] Nitrogen was flushed into a dry three-necked flask, 20 mL of anhydrous methanol was added, 2 g of compound 1 was added to methanol, and 0.19 g of sodium hydroxide was added, and the mixture was heated to 65 ° C and refluxed with stirring for 15 hours. The solvent was concentrated to remove the solvent, and 20 mL of dichloromethane was added and concentrated. 20 mL of ethyl acetate was added to the residue, and the mixture was heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, and the filter cake was washed with 10 mL of ethyl acetate. The filter cake was dried to obtain 1.5 g of sodium salt of diedaravone phosphate (compound 6). LCMS (E-) m / z: 411.4 (M+H).
[0144]
[0145] Embodiment 24:
[0146] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous methanol was added, 2 g of compound 1 was added to methanol, and 0.92 mL of 30% sodium methoxide methanol solution was added, and the mixture was heated to 65 ° C and refluxed for 15 hours. The solvent was removed by concentration, and 20 mL of dichloromethane was added and concentrated. 20 mL of ethyl acetate was added to the residue, and the mixture was heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, and the filter cake was washed with 10 mL of ethyl acetate. The filter cake was dried to obtain 1.69 g of sodium salt of diedaravone phosphate (compound 6). LCMS (E-) m / z: 411.4 (M+H).
[0147] Embodiment 25:
[0148] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous ethanol was added, 2 g of compound 1 was added to ethanol, and 1.57 g of 21% sodium ethanol ethanol solution was added, and heated to 70 ° C and stirred for 12 hours. The solvent was concentrated to remove the solvent, and 20 mL of dichloromethane was added and concentrated. 20 mL of ethyl acetate was added to the residue, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 1.65 g of sodium salt of bis-edaravone phosphate (compound 6). LCMS (E-) m / z: 411.4 (M+H).
[0149] Embodiment 26:
[0150] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous methanol was added, 2 g of compound 1 was added to methanol, and 0.27 g of potassium hydroxide was added, and the mixture was heated to 65 ° C and refluxed for 15 hours. The solvent was concentrated to remove the solvent, and 20 mL of dichloromethane was added and concentrated. 20 mL of ethyl acetate was added to the residue, and the mixture was heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 1.6 g of potassium salt of diedaravone phosphate (compound 7). LCMS (E-) m / z: 411.4 (M+H).
[0151]
[0152] Embodiment 27:
[0153] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous methanol was added, 2 g of compound 1 was added to methanol, and 0.55 g of potassium tert-butoxide was added, and the mixture was heated to 65 ° C and refluxed for 15 hours. The solvent was concentrated to remove the solvent, and 20 mL of dichloromethane was added and concentrated. 20 mL of ethyl acetate was added to the residue, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 1.70 g of potassium salt of diedaravone phosphate (compound 7). LCMS (E-) m / z: 411.4 (M+H).
[0154] Embodiment 28:
[0155] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous methanol was added, 2 g of compound 1 was added to methanol, and 0.12 g of lithium hydroxide was added, and the mixture was heated to 65 ° C and refluxed for 15 hours. The solvent was concentrated to remove the solvent, and 20 mL of dichloromethane was added and concentrated. 20 mL of ethyl acetate was added to the residue, and the mixture was heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 1.4 g of lithium salt of diedaravone phosphate (compound 8). LCMS (E-) m / z: 411.4 (M+H).
[0156]
[0157] Embodiment 29:
[0158] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous methanol was added, 2 g of compound 1 was added to methanol, 0.28 g of magnesium hydroxide was added, and 2 drops of DMF were added. Heat to 65 ° C and reflux with stirring for 100 hours. Concentrate to remove the solvent, add 20 mL of dichloromethane, and concentrate. Add 20 mL of ethyl acetate to the residue, heat to 60 ° C and stir for 2 hours. Cool to room temperature, filter, wash the filter cake with 10 mL of ethyl acetate, and dry the filter cake to obtain 1.2 g of magnesium salt of diedaravone phosphate (compound 9). LCMS (E-) m / z: 411.4 (M+H).
[0159]
[0160] Embodiment 30:
[0161] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous methanol was added, 2 g of compound 1 was added to methanol, 0.36 g of calcium hydroxide was added, and 2 drops of DMF were added. Heat to 65 ° C and reflux with stirring for 100 hours. Concentrate to remove the solvent, add 20 mL of dichloromethane, and concentrate. Add 20 mL of ethyl acetate to the residue, heat to 60 ° C and stir for 2 hours. Cool to room temperature, filter, wash the filter cake with 10 mL of ethyl acetate, and dry the filter cake to obtain 1.2 g of diedaravone phosphate calcium salt (compound 10). LCMS (E-) m / z: 411.4 (M+H).
[0162]
[0163] Embodiment 31:
[0164] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous methanol was added, 2 g of compound 1 was added to methanol, and 0.30 g of ethanolamine was added, and the mixture was heated to 65 ° C and refluxed with stirring for 15 hours. The solvent was concentrated and removed. The resulting residue was added to 20 mL of ethyl acetate, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 2.1 g of bis-edaravone phosphate ethanolamine salt (compound 11). LCMS (E-) m / z: 411.4 (M+H).
[0165]
[0166] Embodiment 32:
[0167] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous ethanol was added, 2 g of compound 1 was added to ethanol, and 0.30 g of ethanolamine was added, and the mixture was heated to 78 ° C and refluxed with stirring for 8 hours. The solvent was concentrated and removed. The resulting residue was added to 20 mL of ethyl acetate, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 2.0 g of bis-edaravone phosphate ethanolamine salt (compound 11). LCMS (E-) m / z: 411.4 (M+H).
[0168] Embodiment 33:
[0169] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous isopropanol was added, 2 g of compound 1 was added to isopropanol, and 0.30 g of ethanolamine was added, and the mixture was heated to 82 ° C and refluxed with stirring for 8 hours. The solvent was concentrated and removed. The resulting residue was added to 20 mL of ethyl acetate, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 2.0 g of bis-edaravone phosphate ethanolamine salt (compound 11). LCMS (E-) m / z: 411.4 (M+H).
[0170] Embodiment 34:
[0171] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous methanol was added, 2 g of compound 1 was added to methanol, and 0.22 g of ethylamine was added, and the mixture was heated to 65 ° C and refluxed for 15 hours. The solvent was concentrated and removed. The resulting residue was added to 20 mL of ethyl acetate, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 1.96 g of bis-edaravone phosphate ethylamine salt (compound 12). LCMS (E-) m / z: 411.4 (M+H).
[0172]
[0173] Embodiment 35:
[0174] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous isopropanol was added, 2 g of compound 1 was added to isopropanol, and 0.49 g of triethylamine was added, and the mixture was heated to 82 ° C and refluxed with stirring for 20 hours. The solvent was concentrated and removed. The resulting residue was added to 20 mL of ethyl acetate, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 2.1 g of triethylamine salt of bisedaravone phosphate (compound 13). LCMS (E-) m / z: 411.4 (M+H).
[0175]
[0176] Embodiment 36:
[0177] In a dry three-necked flask, nitrogen was passed, 20 mL of anhydrous ethanol was added, 2 g of compound 1 was added to ethanol, and 0.42 g of piperazine was added, and the mixture was heated to 78 ° C and refluxed with stirring for 15 hours. The solvent was concentrated and removed. The obtained residue was added to 20 mL of ethyl acetate, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 2.22 g of bis-edaravone phosphate piperazine salt (compound 14). LCMS (E-) m / z: 411.4 (M+H).
[0178]
[0179] Embodiment 37:
[0180] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous ethanol was added, 2 g of compound 1 was added to ethanol, and 1.17 g of dibenzylethylenediamine was added, and the mixture was heated to 78 ° C and refluxed with stirring for 15 hours. The solvent was concentrated and removed. The resulting residue was added to 20 mL of ethyl acetate, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 2.30 g of dibenzylethylenediamine phosphate (compound 15). LCMS (E-) m / z: 411.4 (M+H).
[0181]
[0182] Embodiment 38:
[0183] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous methanol was added, 2 g of compound 1 was added to methanol, and 0.95 g of meglumine was added, and the mixture was heated to 65 ° C and refluxed for 15 hours. The solvent was concentrated and removed. The residue was added to 20 mL of ethyl acetate, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 2.13 g of diedaravone phosphate meglumine salt (compound 16). LCMS (E-) m / z: 411.4 (M+H).
[0184]
[0185] Embodiment 39:
[0186] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous ethanol was added, 2 g of compound 1 was added to ethanol, and 0.59 g of choline was added, and the mixture was heated to 78 ° C and refluxed for 15 hours. The solvent was concentrated and removed. The residue was added to 20 mL of ethyl acetate, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 2.05 g of bisedaravone phosphate choline salt (compound 17). LCMS (E-) m / z: 411.4 (M+H).
[0187]
[0188] Embodiment 40:
[0189] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous ethanol was added, 2 g of compound 1 was added to ethanol, and 0.85 g of arginine was added, and the mixture was heated to 78 ° C and refluxed for 15 hours. The solvent was concentrated and removed. The residue was added to 20 mL of ethyl acetate, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 2.13 g of bis-edaravone phosphate arginine salt (compound 18). LCMS (E-) m / z: 411.4 (M+H).
[0190]
[0191] Embodiment 41:
[0192] Nitrogen was passed into a dry three-necked flask, 20 mL of anhydrous ethanol was added, 2 g of compound 1 was added to ethanol, and 0.71 g of lysine was added, and the mixture was heated to 78 ° C and refluxed with stirring for 15 hours. The solvent was concentrated and removed. The resulting residue was added to 20 mL of ethyl acetate, heated to 60 ° C and stirred for 2 hours. Cooled to room temperature, filtered, the filter cake was washed with 10 mL of ethyl acetate, and the filter cake was dried to obtain 2.11 g of bis-edaravone phosphate lysine salt (compound 19). LCMS (E-) m / z: 411.4 (M+H).
[0193]
[0194] Example 42 Bioavailability Study
[0195] Drugs tested:
[0196] Edaravone raw material powder and Edaravone series prodrug compound powder prepared by the present invention (bisedaravone phosphate, isomers or pharmaceutically acceptable salts thereof)
[0197] Animal conditions:
[0198] The experimental animals were SD rats, half male and half female, weighing 200±20g, provided by the Experimental Animal Center of Southeast University. The experimental animals were caged, with 2 animals of the same sex in each cage. The basic feed was complete pellet feed for experimental mice, provided by the Jiangpu Experimental Animal Feed Factory of Jiangsu Province, with free drinking water; the laboratory temperature was 25±2℃, the humidity was 55±15%, and there was exhaust ventilation equipment. Experimental methods and dosage:
[0199] The experimental animals were randomly divided into groups and fasted for 10 hours. The Edaravone raw material powder and the Edaravone series prodrug compound powder were taken and prepared into solutions or suspensions with physiological saline, and then the rats in each group were gavaged with equal molar amounts of the Edaravone raw material and the Edaravone series prodrug compound. The HPLC method was used to detect the Edaravone content in the plasma at the predetermined time (0, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 12.0, 16.0 and 24.0h), and the bioavailability was calculated. The results are shown in the table:
[0200]
[0201] Pharmacological experiments show that the edaravone prodrug compound provided by the present invention has good solubility and stability, and its oral bioavailability in rats is significantly improved, which is superior to the edaravone raw material drug and has the potential for further clinical research.
[0202] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, a person skilled in the art should understand that it is still possible to modify the technical solutions described in the aforementioned embodiments, or to perform equivalent replacements on some of the technical features therein. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A compound represented by formula I, or a pharmaceutically acceptable salt thereof, in, R1 represents hydrogen, cyclohexyl, phenyl or benzyl; The pharmaceutically acceptable salt is a metal salt or an organic amine salt, wherein the metal salt is a lithium salt, a sodium salt, a potassium salt, a magnesium salt or a calcium salt; and the organic amine salt is an ethylamine salt, a triethylamine salt, an ethanolamine salt, a piperazine salt, a dibenzylethylenediamine salt, a meglumine salt, a choline salt, a lysine salt or an arginine salt.
2. A pharmaceutically acceptable organic amine salt of the compound represented by formula III, in, The organic amine salt is ethylamine salt, triethylamine salt, ethanolamine salt, piperazine salt, dibenzylethylenediamine salt, meglumine salt, choline salt, lysine salt or arginine salt.
3. The compound or its pharmaceutically acceptable salt is selected from:
4. A pharmaceutical composition comprising the compound according to claim 1, 2 or 3 or a pharmaceutically acceptable salt thereof as an active ingredient or a main active ingredient, and supplemented with a pharmaceutically acceptable carrier.
5. Use of the compound according to claim 1, 2 or 3 or a pharmaceutically acceptable salt thereof in the preparation of drugs related to brain protective agents.
Citation Information
Patent Citations
Water-soluble derivatives of edaravone, preparation method and application thereof
CN102190622A
3-methyl-1-phenyl-2-pyrazoline-5-ketone derivant, and preparation method and application thereof
CN102321121A
